We use our powerful precisionlife multi-omic analysis platform to screen genomic, phenotypic and patient health datasets, providing unique insights into the signatures driving complex diseases.
We rapidly identify novel targets, biomarkers and drug candidates enabling the discovery and delivery of precision medicines.
We have shown that these disease signatures can lead us to validated targets, drug discovery opportunities and better personalized medicine.
Fast, Scalable Innovation Engine
We’ve identified and validated targets with potential lead candidates and precision medicine biomarkers for multiple diseases including those below
Our Business Model
We’re building a TargetBank™ containing partner-ready assets with biological data packages demonstrating their R&D, clinical and commercial disease relevance.
Interested in licensing or partnering?
26th November 2019, Oxford and Cambridge, United Kingdom precisionlife and PharmEnable have announced a new drug discovery partnership, collaborating to develop novel treatments for Amyotrophic Lateral Sclerosis (ALS). They are joined by disease researchers at the...
Building on its guiding principles of insight and innovation, AI-enabled precision medicine company RowAnalytics Ltd has undertaken a comprehensive rebrand to become PrecisionLife Ltd, culminating in the launch of a new website and early-stage partnering model. The...
Funding from global investors Astia Angels and Wheatsheaf Group will help bring innovative AI enabled analytics to an international audience Oxford, United Kingdom - March 8th, 2018 — RowAnalytics Ltd announced today that it has secured seed round investment from...
There are no upcoming events.
We are proud to be certified carbon neutral, achieved by proactively reducing our carbon footprint and offsetting our remaining carbon emissions. We chose the Climate Care BURN Stoves project, which won the 2015 Ashden International Clean Energy for Women and Girls Award.
Equality and Diversity
We are an equal opportunities employer. We ensure that no employee or prospective employee receives less favourable treatment on the grounds of gender, sexual orientation, marital status, disability, race, colour or national origin.